利妥昔单抗治疗中国难治性特发性膜性肾病队列研究
该研究纳入36例对既往免疫抑制治疗无应答的特发性膜性肾病患者,使用利妥昔单抗进行B细胞清除治疗。结果显示41.7%的患者获得部分或完全缓解,缓解者抗PLA2R抗体水平较低且肾功能稳定,提示利妥昔单抗可用于难治性iMN并可用抗PLA2R抗体监测。
要点
- 利妥昔单抗可使41.7%的难治性iMN患者获得部分或完全缓解。
- 基线抗PLA2R抗体水平较低者更可能对利妥昔单抗应答。
- 应答者肾功能稳定,无应答者肾功能下降。
核心结论
- 利妥昔单抗治疗可诱导难治性iMN患者蛋白尿缓解并稳定肾功能,即使肾功能已受损。
- 抗PLA2R抗体可作为个体化利妥昔单抗剂量和治疗监测的标志物。
研究设计与样本
- 研究纳入36例对既往免疫抑制治疗无应答的特发性膜性肾病患者。
- 利妥昔单抗用于B细胞清除,目标为循环B细胞<5个/mm3。
- 研究完成后中位随访12.0个月(IQR 9.0-19.3)。
主要发现
- 36例中15例(41.7%)获得部分(n=13)或完全(n=2)缓解。
- 达到部分缓解的中位时间为4.0个月(IQR 3.0-6.0)。
- 缓解者基线抗PLA2R抗体水平较低(118±112 U/mL vs 345±357 U/mL,P=0.03),且均实现抗体清除或下降。
- 所有患者均实现B细胞清除。
- 缓解者eGFR保持稳定(53.3±40.5 vs 55.6±33.2 mL/min/1.73 m2,P=0.67),无应答者eGFR下降(57.5±29.3 vs 45.3±32.8 mL/min/1.73 m2,P=0.02),其中2例进展至终末期肾病。
临床怎么用
- 对既往免疫抑制治疗无应答的iMN患者可考虑利妥昔单抗治疗。
- 治疗期间监测抗PLA2R抗体水平有助于评估应答和个体化调整剂量。
- B细胞清除可作为治疗目标进行监测。
局限性
- 研究为单臂设计,样本量36例,无对照组。
- 随访时间中位12.0个月,长期疗效和安全性未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rituximab had been shown to be effective in inducing remission of nephrotic syndrome in patients with idiopathic membranous nephropathy (iMN). This study applied rituximab therapy for 36 non-responsive iMN patients to investigate its effects and safety. METHODS: Thirty-six iMN patients who were non-responsive to prior immunosuppression were enrolled. Rituximab was used for B-cell depletion in patients, with a goal of <5 B cells/mm3 in the circulation. After completing the study, patients were monitored for a median of 12.0 months [interquartile range (IQR) 9.0-19.3]. RESULTS: Fifteen of the 36 (41.7%) patients achieved partial (n = 13) or complete (n = 2) response to the rituximab treatment. The median time for achieving partial response was 4.0 months (IQR 3.0-6.0). The responders had relatively lower levels (118 ± 112 U/mL versus 345 ± 357 U/mL, P = 0.03) of anti-phospholipase 2 receptor (PLA2R) antibodies before the rituximab treatment, and all of them achieved antibody depletion or reduction. B-cell depletion was achieved in all patients. Renal function remained stable in the responders [estimated glomerular filtration rate (eGFR) 53.3 ± 40.5 versus 55.6 ± 33.2 mL/min/1.73 m2, P = 0.67] but deteriorated in the non-responders (eGFR 57.5 ± 29.3 versus 45.3 ± 32.8 mL/min/1.73 m2, P = 0.02) with two patients reaching end-stage kidney disease. Two of the 15 patients relapsed during the follow-up period with anti-PLA2R antibody reoccurrence and B-cell reconstitution. The second course of rituximab combined with tacrolimus induced a faster partial response again in one patient. CONCLUSION: Rituximab therapy could induce remission of proteinuria and stabilization of renal function in non-responsive iMN patients, even those with damaged renal function. Anti-PLA2R antibodies may be used as a marker for individualized rituximab dosage and treatment monitoring.
引用
- Wang X, Cui Z, Zhang YM, et al. Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort. Nephrol Dial Transplant. 2018. PMID: 29149305. doi:10.1093/ndt/gfx295
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。